Borland Gillian, Gupta Mona, Magiera Maria M, Rundell Catherine J, Fuld Suzanne, Yarwood Stephen J
Molecular Pharmacology Group, Division of Biochemistry and Molecular Biology, Faculty of Biomedical and Life Sciences, University of Glasgow, Glasgow, Scotland, United Kingdom.
Mol Pharmacol. 2006 Jan;69(1):374-84. doi: 10.1124/mol.105.016337. Epub 2005 Oct 21.
We have previously demonstrated that EPAC1 interacts with light chain (LC) 2 of microtubule-associated protein (MAP) 1A. In the present study, we investigated whether the structurally related LC1 of MAP1B also interacts with EPAC1. We demonstrate that LC1 copurifies with EPAC1 from extracts of PC-12 cells, using cyclic AMP-agarose. Using recombinant LC1 and LC2 in pull-down and solid phase binding assays, we demonstrate direct interaction with a glutathione S-transferase-fusion of the cyclic AMP-binding (CAMP) domain of EPAC1. We also tested whether LC1 directed intracellular targeting of EPAC1 through its interaction with the CAMP domain. EPAC1 was found be in the soluble and particulate, nuclear/perinuclear fractions of cells. We found that the catalytic (CAT) domain of EPAC1, and not the CAMP domain, was responsible for recruitment to the nuclear/perinuclear fraction of cells. The targeting sequence responsible was located between amino acids 764 and 838 of EPAC1. Overexpresssion of an isolated CAT domain in COS1 cells was found to displace endogenous EPAC1 from the nuclear/perinuclear fraction, thereby inhibiting EPAC-activated Rap1 in this compartment. In contrast, LC1 was not able to compete for the binding of EPAC1 to this fraction. LC1, however, was able to enhance interaction of EPAC1 with cyclic AMP and heightened the ability of EPAC to activate Rap1. Antibody disruption of EPAC1/LC1 interaction in PC-12 cells ablated the ability of cyclic AMP to activate Rap1. LC1 is therefore not involved in intracellular targeting of EPAC1, but it is rather a molecular chaperone of EPAC activity toward Rap1.
我们之前已经证明,交换蛋白直接激活环磷腺苷效应肽1(EPAC1)与微管相关蛋白(MAP)1A的轻链(LC)2相互作用。在本研究中,我们调查了结构相关的MAP1B的LC1是否也与EPAC1相互作用。我们证明,使用环磷腺苷琼脂糖,LC1可从PC-12细胞提取物中与EPAC1共纯化。在下拉和固相结合试验中使用重组LC1和LC2,我们证明其与EPAC1的环磷腺苷结合(CAMP)结构域的谷胱甘肽S-转移酶融合体直接相互作用。我们还测试了LC1是否通过其与CAMP结构域的相互作用指导EPAC1的细胞内靶向。发现EPAC1存在于细胞的可溶性和颗粒性、核/核周部分。我们发现,EPAC1的催化(CAT)结构域而非CAMP结构域负责其募集到细胞的核/核周部分。负责的靶向序列位于EPAC1的764至838位氨基酸之间。在COS1细胞中过表达分离的CAT结构域可将内源性EPAC1从核/核周部分置换出来,从而抑制该隔室内EPAC激活的Rap1。相比之下,LC1无法竞争EPAC1与该部分的结合。然而,LC1能够增强EPAC1与环磷腺苷的相互作用,并提高EPAC激活Rap1的能力。PC-12细胞中EPAC1/LC1相互作用的抗体破坏消除了环磷腺苷激活Rap1的能力。因此,LC1不参与EPAC1的细胞内靶向,而是EPAC对Rap1活性的分子伴侣。